A research study on dapagliflozin on urinary albumin defecation in patients with chronic kidney disease
1Dr Nida Gohar, 2Dr Ali RAza, 3Dr Haris Noor, 4Bilal Shabbir, 5Dr. Saad Ahmad, 6Dr Muhammad Asad Ashfaq 7Ahmad Farooq, 8Kashif Lodhi,
1Consultant Medicine/UhB ITF in Endocrinology and Diabetes
2SR Medicine, Shahida Islam Medical Complex, Lodhran, Pakistan
3Poonch Medical College Rawalakot Azad Kashmir
4Poonch Medical College Rawalakot
5Demonstrator, Foundation University Medical College, Islamabad
6Medical Officer, DHQ Hospital Vehari
7Dr faisal masood teaching hospital Sargodha
8Department of Agricultural, Food and Environmental Sciences. Università Politécnica delle Marche Via
Brecce Bianche 10, 60131 Ancona (AN) Italy
Vol: 16/03
Received: January 25, 2026 Accepted: March 02, 2026 Published: July 06, 2026
ABSTRACT:Background: Chronic kidney disease (CKD) poses a significant health burden globally, often associated with complications such as increased urinary albumin excretion, which is a marker of kidney damage and cardiovascular risk. Dapagliflozin, a sodium-glucose co-transporter 2 inhibitor, has shown promising results in reducing albuminuria in patients with type 2 diabetes. However, its efficacy in patients with CKD remains to be fully elucidated. Aim: This retrospective study aimed to evaluate the impact of dapagliflozin treatment on urinary albumin excretion in patients diagnosed with CKD. Methods: Medical records of patients diagnosed with CKD who were prescribed dapagliflozin were retrospectively analyzed. Patients with baseline and follow-up measurements of urinary albumin excretion were included in the study. Changes in urinary albumin excretion from baseline to follow-up were assessed. Results: A total of 120 patients with CKD met the inclusion criteria and were included in the analysis. The mean duration of dapagliflozin treatment was February 2023 to January 2024. Following treatment initiation, a statistically significant reduction in urinary albumin excretion was observed in 67% of patients (p < 0.05). Conclusion: Our retrospective analysis suggests that dapagliflozin may have a beneficial effect on reducing urinary albumin excretion in patients with CKD. These findings warrant further investigation through prospective randomized controlled trials to confirm the efficacy and safety of dapagliflozin in this patient population. Keywords: Dapagliflozin, chronic kidney disease, urinary albumin excretion, sodium-glucose cotransporter 2 inhibitors, retrospective analysis.